Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.

Medicine - 1 May 2017

Liang Jin-Yan, Tong Fan, Gu Fei-Fei, Liu Yang-Yang, Zeng Yu-Lan, Hong Xiao-Hua, Zhang Kai, Liu Li

Abstract excerpt

RATIONALE: Lung cancer is the leading cause of cancer-related death in the world. Tyrosine kinase inhibitors (TKIs), which target mutated epidermal growth factor receptor (EGFR), have been the first-line treatment of late-stage lung adenocarcinoma harboring EGFR mutation. EGFR mutations are mostly identified in lung adenocarcinoma. However, it is rarely seen in lung neuroendocrine carcinoma, and treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Albumins
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Neuroendocrine

Share to Erlotinib Hydrochloride

Share to Fatal Outcome

Share to Liver Neoplasms

Share to Paclitaxel

Source

Open in PubMed Open full text

Identifiers

PMID: 28538405
DOI: 10.1097/MD.0000000000006985
PMCID: PMC5457885

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.PMID 28538405Read ↗

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.Semantic proximity Read ↗

BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: a case report and review of the literature.Semantic proximity Read ↗

The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the LungSemantic proximity Read ↗

Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.Semantic proximity Read ↗

Biology and novel therapeutics for neuroendocrine tumors of the lung.Semantic proximity Read ↗

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.Semantic proximity Read ↗

ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literatureSemantic proximity Read ↗

Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes.Semantic proximity Read ↗

Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?Semantic proximity Read ↗

Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.Semantic proximity Read ↗

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.Semantic proximity Read ↗

p53+/-Rb1-ASCL1low Phenotype Predicts Better Prognosis After Surgical Resection in Large Cell Neuroendocrine Carcinoma: a Molecular Characteristic and Clinical-pathological Investigation of Lung Neuroendocrine TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.